Colombia and Mexico health analyses expose drug overpricing and private hospital gaps

A study by Colombia's Ministry of Finance and Public Credit together with the Institute for Technological Evaluation in Health (IETS) identified extreme price deviations for some medicines, with recorded values reaching up to 1,834 times the maximum regulated price. The analysis also highlighted wide variations in hospital costs and atypical frequencies for certain diagnostic tests. The report stresses that the findings are statistical signals for further verification and do not constitute an audit or proof of fraud.

Mexico's latest report from the National Institute of Statistics and Geography (INEGI) shows that the private health sector is highly concentrated: of the 2,689 private hospitals with licensed beds, more than half are located in just 59 municipalities, and 55.4% are in seven states. Most private facilities are small, with fewer than ten beds, reflecting a fragmented market that expands where public services are lacking but does not ensure universal health coverage.

Both analyses point to systemic inefficiencies and inequality in health provision across the two countries, underscoring the need for stronger oversight and policies to address cost overruns and uneven access.